Anacor veterans raise $80M in bid to tackle rare lung disease with boron-based inhibitors
After starting up with a $12 million Series A in 2019, California outfit AN2 Therapeutics issued its first press release in over 2 years — and its second ever: The ultra-quiet biotech has raised an $80 million Series B and added a pair of directors to boot.
The biotech is headed by several leaders from Anacor, which was bought out by Pfizer in 2016 for about $5.2 billion. Eric Easom, former head of Anacor’s R&D on neglected diseases, is co-founder and CEO. Other Anacor vets include AN2’s chief development officer, CFO and head of biology.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.